MTX could decrease plasma levels of TNF-α, IL-1β, IL-6, IL-17, and IL-23 in RA patients (Lina et al. 2011), in addition to serum levels of TNF-α, and IL-6 in CFA rats (Azouz et al. 2020). This evidence concerns the gene IL6 and rheumatoid arthritis.